Potential Effects of Silymarin and Its Flavonolignan Components in Patients with β-Thalassemia Major: A Comprehensive Review in 2015
Major β-thalassemia (β-TM) is one of the most common inherited hemolytic types of anemia which is caused as a result of absent or reduced synthesis of β-globin chains of hemoglobin. This defect results in red blood cells lysis and chronic anemia that can be treated by multiple blood transfusions and...
Saved in:
Main Authors: | Hadi Darvishi Khezri (Author), Ebrahim Salehifar (Author), Mehrnoush Kosaryan (Author), Aily Aliasgharian (Author), Hossein Jalali (Author), Arash Hadian Amree (Author) |
---|---|
Format: | Book |
Published: |
Hindawi Limited,
2016-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Silymarin therapy and improvement of cardiac outcome in patients with β-thalassemia major
by: Hadi Darvishi Khezri, et al.
Published: (2016) -
Treatment Status of Patients with Β-Thalassemia Major in Northern Iran: Thalassemia Registry System
by: Mehrnoush KOSARYAN, et al.
Published: (2019) -
Decrease of Hepatitis C Burden in Patients With Transfusion Dependent Beta Thalassemia Major, Thalassemia Research Center, 1995 - 2014
by: Mehrnoush Kosaryan, et al.
Published: (2015) -
Decrease of Hepatitis C Burden in Patients With Transfusion Dependent Beta Thalassemia Major, Thalassemia Research Center, 1995 - 2014
by: Mehrnoush Kosaryan, et al.
Published: (2015) -
In Vitro Hb Production in Β-thalassemia Patients Is Not a Predictor of Clinical Responsiveness to Hydroxyurea
by: Mohammad Reza MAHDAVI, et al.
Published: (2017)